Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs

Journal of Pharmaceutical Sciences

Volumn 106, Issue 9, 2017, Pages 2234-2244

  Ehrhardt, Carsten ^a   Bäckman, Per ^b   Couet, William ^c   Edwards, Chris ^d   Forbes, Ben ^e   Fridén, Markus ^f,g   Gumbleton, Mark ^h   Hosoya, Ken Ichi ⁱ   Kato, Yukio ^j   Nakanishi, Takeo ^j   Takano, Mikihisa ^k   Terasaki, Tetsuya ^l   Yumoto, Ryoko ^k  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Global Respiratory Group   (United Kingdom)

^c UNIVERSITÉ DE POITIERS   (France)

^d GLAXOSMITHKLINE   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UPPSALA UNIVERSITY   (Sweden)

^g ASTRAZENECA R AND D   (Sweden)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY OF TOYAMA   (Japan)

^j KANAZAWA UNIVERSITY   (Japan)

^k HIROSHIMA UNIVERSITY   (Japan)

^l TOHOKU UNIVERSITY   (Japan)

more..

Author keywords

ABC transporters; absorption; computational ADME; efflux pumps; in vitro models; organic anion transporting polypeptide transporters; organic cation transporters; P glycoprotein; peptide transporters; pulmonary delivery absorption

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; BRONCHODILATING AGENT; CARNITINE TRANSPORTER 1; CIPROFLOXACIN; ELACRIDAR; FENOTEROL; FORMOTEROL; GLYCOPROTEIN; INDACATEROL; IPRATROPIUM BROMIDE; LEVOFLOXACIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 6; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 8; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 5; OLODATEROL; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; ORGANIC ANION TRANSPORTER B; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PEPTIDE TRANSPORTER 2; SALBUTAMOL; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; UNINDEXED DRUG; CARRIER PROTEIN; DRUG;

CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG DISPOSITION; DRUG EXPOSURE; DRUG PROTEIN BINDING; DRUG TRANSPORT; EPITHELIUM CELL; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; NONHUMAN; PERMEABILITY BARRIER; PHARMACOKINETIC PARAMETERS; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; PROTEOMICS; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGULATORY MECHANISM; WORKSHOP; ANIMAL; LUNG; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; LUNG; LUNG DISEASES; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS;

EID: 85019389416     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2017.04.011     Document Type: Conference Paper

References (111)

1. Gumbleton, M., Al-Jayyoussi, G., Crandon-Lewis, A., et al. Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. Adv Drug Deliv Rev 63:1–2 (2011), 110–118.
2. Nickel, S., Clerkin, C.G., Selo, M.A., Ehrhardt, C., Transport mechanisms at the pulmonary mucosa: implications for drug delivery. Expert Opin Drug Deliv 13:5 (2016), 667–690.
3. Bosquillon, C., Drug transporters in the lung—do they play a role in the biopharmaceutics of inhaled drugs?. J Pharm Sci 99:5 (2010), 2240–2255.
4. Gustavsson, L., Bosquillon, C., Gumbleton, M., et al. Drug transporters in the lung: expression and potential impact on pulmonary drug disposition. Nicholls, G., Youdim, K., (eds.) Drug Transporters: Role and Importance in ADME and Drug Development, 2016, RSC, London, 184–227.
5. Kamiie, J., Ohtsuki, S., Iwase, R., et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:6 (2008), 1469–1483.
6. Ohtsuki, S., Uchida, Y., Kubo, Y., Terasaki, T., Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy and prospects. J Pharm Sci 100:9 (2011), 3547–3559.
7. Uchida, Y., Ohtsuki, S., Terasaki, T., Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy and phenytoin treatment models. Drug Metab Dispos 42:10 (2014), 1719–1726.
8. Sakamoto, A., Matsumaru, T., Yamamura, N., et al. Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender and inter-individual differences by liquid chromatography-tandem mass spectrometry. J Pharm Sci 102:9 (2013), 3395–3406.
9. Ohtsuki, S., Kawakami, H., Inoue, T., et al. Validation of uPA/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS. Drug Metab Dispos 42:6 (2014), 1039–1043.
10. Akazawa, T., Uchida, Y., Tachikawa, M., Ohtsuki, S., Terasaki, T., Quantitative targeted absolute proteomics of transporters and pharmacoproteomics-based reconstruction of P-glycoprotein function in mouse small intestine. Mol Pharm 13:7 (2016), 2443–2456.
11. Sakamoto, A., Suzuki, S., Matsumaru, T., et al. Correlation of OCTN1 and MRP1 transport activities with protein expression levels in primary cultured human tracheal, bronchial and alveolar epithelial cells. J Pharm Sci 105:2 (2016), 876–883.
12. Sakamoto, A., Matsumaru, T., Yamamura, N., et al. Drug transporter protein quantification of immortalized human lung cell lines derived from tracheo-bronchial epithelial cells (Calu-3 and BEAS2-B), bronchiolar-alveolar cells (NCI-H292 and NCI-H441) and alveolar type II-like cells (A549) by liquid chromatography-tandem mass spectrometry. J Pharm Sci 104:9 (2015), 3029–3038.
13. Forbes, B., Ehrhardt, C., Human respiratory epithelial cell culture for drug delivery application. Eur J Pharm Biopharm 60:2 (2005), 193–205.
14. Sporty, J.L., Horálková, L., Ehrhardt, C., In vitro cell culture models for the assessment of pulmonary drug disposition. Expert Opin Drug Metab Toxicol 4:4 (2008), 333–345.
15. Ehrhardt, C., Kneuer, C., Fiegel, J., et al. Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o-: implications for the use of this cell line as an in vitro model for bronchial drug absorption studies. Cell Tissue Res 308:3 (2002), 391–400.
16. Lin, H., Li, H., Cho, H.J., et al. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J Pharm Sci 96:2 (2007), 341–350.
17. Benediktsdóttir, B.E., Arason, A.J., Halldórsson, S., Gudjónsson, T., Másson, M., Baldursson, O., Drug delivery characteristics of the progenitor bronchial epithelial cell line VA10. Pharm Res 30:3 (2010), 781–791.
18. Zabner, J., Karp, P., Seiler, M., et al. Development of cystic fibrosis and noncystic fibrosis airway cell lines. Am J Physiol Lung Cell Mol Physiol 284:5 (2003), L844–L854.
19. Fulcher, M.L., Gabriel, S.E., Olsen, J.C., et al. Novel human bronchial epithelial cell lines for cystic fibrosis research. Am J Physiol Lung Cell Mol Physiol 296:1 (2009), L82–L91.
20. Walters, M.S., Gomi, K., Ashbridge, B., et al. Generation of a human airway epithelium derived basal cell line with multipotent differentiation capacity. Respir Res, 14, 2013, 135.
21. Kuehn, A., Kletting, S., de Souza Carvalho-Wodarz, C., et al. Human alveolar epithelial cells expressing tight junctions to model the air-blood barrier. ALTEX 33:3 (2016), 251–260.
22. Tronde, A., Nordén, B., Jeppsson, A.-B., et al. Drug absorption from the isolated perfused rat lung—correlations with drug physicochemical properties and epithelial permeability. J Drug Target 11:1 (2003), 61–74.
23. Mathia[s], N.R., Timoszyk, J., Stetsko, P.I., Megill, J.R., Smith, R.L., Wall, D.A., Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J Drug Target 10:1 (2002), 31–40.
24. Manford, F., Tronde, A., Jeppsson, A.B., Patel, N., Johansson, F., Forbes, B., Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. Eur J Pharm Sci 26:5 (2005), 414–420.
25. Cooper, A.E., Ferguson, D., Grime, K., Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metabol 13:4 (2012), 457–473.
26. Rodgers, T., Leahy, D., Rowland, M., Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:6 (2005), 1259–1276.
27. Kakee, A., Terasaki, T., Sugiyama, Y., Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharm Exp Ther 277:3 (1996), 1550–1559.
28. Bäckström, E., Boger, E., Lundqvist, A., Hammarlund-Udenaes, M., Fridén, M., Lung retention by lysosomal trapping of inhaled drugs can be predicted in vitro with lung slices. J Pharm Sci 105:11 (2016), 3432–3439.
29. Nakamura, T., Nakanishi, T., Haruta, T., Shirasaka, Y., Keogh, J.P., Tamai, I., Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm 7:1 (2010), 187–195.
30. Bäckström, E., Lundqvist, A., Boger, E., et al. Development of a novel lung slice methodology for profiling of inhaled compounds. J Pharm Sci 105:2 (2016), 838–845.
31. Salomon, J.J., Hagos, Y., Petzke, S., et al. Beta-2 adrenergic agonists are substrates and inhibitors of human organic cation transporter 1. Mol Pharm 12:8 (2015), 2633–2641.
32. Dudley, A.J., Bleasby, K., Brown, C.D., The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol 131:1 (2000), 717–719.
33. Boger, E., Evans, N., Chappell, M., et al. Systems pharmacology approach for prediction of pulmonary and systemic pharmacokinetics and receptor occupancy of inhaled drugs. CPT Pharmacometrics Syst Pharmacol 5:4 (2016), 201–210.
34. Caniga, M., Cabal, A., Mehta, K., et al. Preclinical experimental and mathematical approaches for assessing effective doses of inhaled drugs, using mometasone to support human dose predictions. J Aerosol Med Pulm Drug Deliv 29:4 (2016), 362–377.
35. th, 2015 in Baltimore, MD. AAPS Open, 2(1), 2016, 1.
36. Forbes, B., Asgharian, B., Dailey, L.A., et al. Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev 63:1–2 (2011), 69–87.
37. Tronde, A., Bosquillon, C., Forbes, B., The isolated perfused lung for drug absorption studies. Ehrhardt, C., Kim, K.J., (eds.) Drug Absorption Studies—In Situ, In Vitro and In Silico Models, 2008, Springer, New York, NY, 135–163.
38. Al-Jayyoussi, G., Price, D.F., Francombe, D., et al. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout. J Pharm Sci 102:9 (2013), 3382–3394.
39. 2-agonists due to competition for organic cation/carnitine transporters. Pulm Pharmacol Ther 25:1 (2012), 124–134.
40. Edwards, C.D., Luscombe, C., Eddershaw, P., Hessel, E.M., Development of a novel quantitative structure-activity relationship model to accurately predict pulmonary absorption and replace routine use of the isolated perfused respiring rat lung model. Pharm Res 33:11 (2016), 2604–2616.
41. Beck-Broichsitter, M., Stoisiek, K., Bohr, A., et al. Potential of the isolated lung technique for the examination of sildenafil absorption from lung-delivered poly(lactide-co-glycolide) microparticles. J Control Release 226 (2016), 15–20.
42. Ong, H.X., Benaouda, F., Traini, D., et al. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. Eur J Pharm Biopharm 86:1 (2014), 83–89.
43. Morris, C.J., Smith, M.W., Griffiths, P.C., McKeown, N.B., Gumbleton, M., Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. J Control Release 151:1 (2011), 83–94.
44. Bayard, F.J.C., Thielemans, W., Pritchard, D.I., et al. Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. J Control Release 171:2 (2013), 234–240.
45. Tronde, A., Nordén, B., Marchner, H., Wendel, A., Lennernäs, H., Bengtsson, U.H., Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure–absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 92:6 (2003), 1216–1233.
46. Manford, F., Riffo-Vasquez, Y., Spina, D., et al. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice. J Pharm Pharmacol 60:10 (2003), 1305–1310.
47. Al-Jayyoussi, G., Price, D.F., Kreitmeyr, K., et al. Absorption of ipratropium and L-carnitine into the pulmonary circulation of the ex-vivo rat lung is driven by passive processes rather than active uptake by OCT/OCTN transporters. Int J Pharm 496:2 (2015), 834–841.
48. Sakagami, M., Omidi, Y., Campbell, L., et al. Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung. Pharm Res 23:2 (2006), 270–279.
49. Sakagami, M., Byron, P.R., Rypacek, F., Biochemical evidence for transcytotic absorption of polyaspartamide from the rat lung: effects of temperature and metabolic inhibitors. J Pharm Sci 91:9 (2002), 1958–1968.
50. Ritchie, T.J., Luscombe, C.N., Macdonald, S.J., Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet?. J Chem Inf Model 49:4 (2009), 1025–1032.
51. Enna, S.J., Schanker, L.S., Absorption of saccharides and urea from the rat lung. Am J Physiol 222:2 (1979), 409–414.
52. Bäckman, P., Tehler, U., Olsson, B., Predicting exposure after oral inhalation of the selective glucocorticoid receptor modulator, AZD5423, based on dose, deposition pattern, and mechanistic modeling of pulmonary disposition. J Aerosol Med Pulm Drug Deliv 30:2 (2017), 108–117.
53. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf Accessed May 2, 2017.
54. Patton, J.S., Byron, P.R., Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:1 (2007), 67–74.
55. Stouch, T.R., Gudmundsson, O., Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54 (2002), 315–328.
56. Bleasby, K., Castle, J.C., Roberts, C.J., et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36 (2006), 963–988.
57. Brady, J.M., Cherrington, N.J., Hartley, D.P., Buist, S.C., Li, N., Klaassen, C.D., Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30 (2002), 838–844.
58. Campbell, L., Abulrob, A.N., Kandalaft, L.E., et al. Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J Pharmacol Exp Ther 304 (2003), 441–452.
59. Endter, S., Becker, U., Daum, N., et al. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res 328:1 (2007), 77–84.
60. Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Casals, D., Bertino, J.R., Melamed, M.R., Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38 (1990), 1277–1278.
61. Valk, P.V.D., Kalken, C.K.V., Ketelaars, H., et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1:1 (1990), 56–64.
62. Lechapt-Zalcman, E., Hurbain, I., Lacave, R., et al. MDR1-Pgp 170 expression in human bronchus. Eur Respir J 10 (1997), 1837–1843.
63. Scheffer, G.L., Pijnenborg, A.C., Smit, E.F., et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 55:5 (2002), 332–339.
64. Kuhlmann, O., Hofmann, H.S., Muller, S.P., Weiss, M., Pharmacokinetics of idarubicin in the isolated perfused rat lung: effect of cinchonine and rutin. Anticancer Drugs 14 (2003), 411–416.
65. Roerig, D.L., Audi, S.H., Ahlf, S.B., Kinetic characterization of P-glycoprotein-mediated efflux of rhodamine 6G in the intact rabbit lung. Drug Metab Dispos 32 (2004), 953–958.
66. Madlova, M., Bosquillon, C., Asker, D., Dolezal, P., Forbes, B., In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity. J Pharm Pharmacol 61 (2009), 293–301.
67. Francombe, D., Taylor, G., Somers, G., Edwards, C.E., Gumbleton, M., Functional role of P-gp efflux in limiting pulmonary drug absorption within an intact lung: application of an isolated perfused rat lung model. Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., (eds.) Respiratory Drug Delivery 2008, Volume II, 2008, Davis Healthcare International Publishing, River Grove, 461–464.
68. Mehta, R., Kelleher, D., Preece, A., Hughes, S., Crater, G., Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Int J Chron Obstruct Pulmon Dis 8 (2013), 159–167.
69. Koepsell, H., The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34:2–3 (2013), 413–435.
70. Hendrickx, R., Johansson, J.G., Lohmann, C., et al. Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem 56:18 (2013), 7232–7242.
71. Salomon, J.J., Ehrhardt, C., Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. Ther Deliv 3:6 (2012), 735–747.
72. Ehrhardt, C., Kneuer, C., Bies, C., Lehr, C.M., Kim, K.J., Bakowsky, U., Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm Pharmacol Ther 18:3 (2005), 165–170.
73. Lips, K.S., Volk, C., Schmitt, B.M., et al. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 33:1 (2005), 79–88.
74. Endter, S., Francombe, D., Ehrhardt, C., Gumbleton, M., RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J Pharm Pharmacol 61:5 (2009), 583–591.
75. Salomon, J.J., Endter, S., Tachon, G., Falson, F., Buckley, S.T., Ehrhardt, C., Transport of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) in human respiratory epithelial cells. Eur J Pharm Biopharm 81:2 (2012), 351–359.
76. Nakanishi, T., Hasegawa, Y., Haruta, T., Wakayama, T., Tamai, I., In vivo evidence of organic cation transporter-mediated tracheal accumulation of the anticholinergic agent ipratropium in mice. J Pharm Sci 102:9 (2013), 3373–3381.
77. Daniel, H., Kottra, G., The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 447 (2004), 610–618.
78. Takano, M., Horiuchi, T., Sasaki, Y., Kato, Y., Nagai, J., Yumoto, R., Expression and function of PEPT2 during transdifferentiation of alveolar epithelial cells. Life Sci 93 (2013), 630–636.
79. Takano, M., Sugimoto, N., Ehrhardt, C., Yumoto, R., Functional expression of PEPT2 in the human distal lung epithelial cell line NCl-H441. Pharm Res 32 (2015), 3916–3926.
80. Swaan, P.W., Bensman, T., Bahadduri, P.M., et al. Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. Am J Respir Cell Mol Biol 39 (2008), 536–542.
81. 11C-nicotine. Proc Natl Acad Sci U S A 107 (2010), 5190–5195.
82. Tega, Y., Yuzurihara, C., Kubo, Y., Akanuma, S., Ehrhardt, C., Hosoya, K., Functional expression of nicotine influx transporter in A549 human alveolar epithelial cells. Drug Metab Pharmacokinet 31 (2016), 99–101.
83. Tega, Y., Akanuma, S., Kubo, Y., Terasaki, T., Hosoya, K., Blood-to-brain influx transport of nicotine at the rat blood-brain barrier: involvement of a pyrilamine-sensitive organic cation transport process. Neurochem Int 62 (2013), 173–181.
84. Ikehata, M., Yumoto, R., Nakamura, K., Nagai, J., Takano, M., Comparison of albumin uptake in rat alveolar type II and type I-like epithelial cells in primary culture. Pharm Res 25:4 (2008), 913–922.
85. Gontijo, A.V., Brillault, J., Grégoire, N., et al. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. Antimicrob Agents Chemother 58:7 (2014), 3942–3949.
86. Gontijo, A.V., Grégoire, N., Lamarche, I., Gobin, P., Couet, W., Marchand, S., Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob Agents Chemother 58:7 (2014), 3950–3956.
87. Marchand, S., Grégoire, N., Brillault, J., Lamarche, I., Gobin, P., Couet, W., Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 3. Tobramycin. Antimicrob Agents Chemother 59:10 (2015), 6646–6647.
88. Marchand, S., Grégoire, N., Brillault, J., Lamarche, I., Gobin, P., Couet, W., Biopharmaceutical characterization of nebulized antimicrobial agents in rats. 4. Aztreonam. Antimicrob Agents Chemother 60:5 (2016), 3196–3198.
89. Galindo Bedor, D.C., Marchand, S., Lamarche, I., Laroche, J., Pereira de Santana, D., Couet, W., Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 5. Oseltamivir carboxylate. Antimicrob Agents Chemother 60:8 (2016), 5085–5087.
90. Brillault, J., De Castro, W.V., Harnois, T., Kitzis, A., Olivier, J.C., Couet, W., P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob Agents Chemother 53:4 (2009), 1457–14621.
91. Tokuhiro, S., Yamada, R., Chang, X., et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35:4 (2003), 341–348.
92. Peltekova, V.D., Wintle, R.F., Rubin, L.A., et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36:5 (2004), 471–475.
93. Hou, X., Mao, J., Li, Y., et al. Association of single nucleotide polymorphism rs3792876 in SLC22A4 gene with autoimmune thyroid disease in a Chinese Han population. BMC Med Genet, 16, 2015, 76.
94. Ben Said, M., Grati, M., Ishimoto, T., et al. A mutation in SLC22A4 encoding an organic cation transporter expressed in the cochlea strial endothelium causes human recessive non-syndromic hearing loss DFNB60. Hum Genet 135:5 (2016), 513–524.
95. Kato, Y., Kubo, Y., Iwata, D., et al. Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. Pharm Res 27:5 (2010), 832–840.
96. Gründemann, D., Harlfinger, S., Golz, S., et al. Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A 102:14 (2005), 5256–5261.
97. Taubert, D., Grimberg, G., Jung, N., Rubbert, A., Schömig, E., Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn’ disease. Gut 54:10 (2005), 1505–1506.
98. Taubert, D., Lazar, A., Grimberg, G., et al. Association of rheumatoid arthritis with ergothioneine levels in red blood cells: a case control study. J Rheumatol 33:11 (2006), 2139–2145.
99. Nickel, S., Selo, M.A., Clerkin, C.G., et al. Ergothioneine protects lung epithelial cells from tobacco smoke-induced oxidative damage in vitro and in vivo. Am J Respir Crit Care Med, 193, 2016, A7514.
100. Kanai, N., Lu, R., Satriano, J.A., Bao, Y., Wolkoff, A.W., Schuster, V.L., Identification and characterization of a prostaglandin transporter. Science 268 (1995), 866–869.
101. Lu, R., Kanai, N., Bao, Y., Schuster, V.L., Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest 98 (1996), 1142–1149.
102. Seifert, W., Kuhnisch, J., Tuysuz, B., Specker, C., Brouwers, A., Horn, D., Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat 33 (2012), 660–664.
103. Umeno, J., Hisamatsu, T., Esaki, M., et al. A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter. PLoS Genet, 11, 2015, e1005581.
104. Vancheri, C., Mastruzzo, C., Sortino, M.A., Crimi, N., The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 25 (2004), 40–46.
105. Chang, H.Y., Locker, J., Lu, R., Schuster, V.L., Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. Circulation 121 (2010), 529–536.
106. Shirasaka, Y., Shichiri, M., Kasai, T., et al. A role of prostaglandin transporter in regulating PGE2 release from human bronchial epithelial BEAS-2B cells in response to LPS. J Endocrinol 217 (2013), 265–274.
107. Nakanishi, T., Hasegawa, Y., Mimura, R., et al. Prostaglandin transporter (PGT/SLCO2A1) protects the lung from bleomycin-induced fibrosis. PLoS One, 10, 2015, e0123895.
108. Huang, S., Wettlaufer, S.H., Hogaboam, C., Aronoff, D.M., Peters-Golden, M., Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 292 (2007), L405–L413.
109. Huang, S.K., Wettlaufer, S.H., Chung, J., Peters-Golden, M., Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. Am J Respir Cell Mol Biol 39 (2008), 482–489.
110. Shimada, H., Nakamura, Y., Nakanishi, T., Tamai, I., OATP2A1/SLCO2A1-mediated prostaglandin E2 loading into intracellular acidic compartments of macrophages contributes to exocytotic secretion. Biochem Pharmacol 98 (2015), 629–638.
111. Dinis-Oliveira, R.J., Duarte, J.A., Sánchez-Navarro, A., Remião, F., Bastos, M.L., Carvalho, F., Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment. Crit Rev Toxicol 38:1 (2008), 13–71.